The linear launch plan, which works through evidence, pricing and access in sequence after pivotal data, is a poor fit for the EU joint clinical assessment (JCA). A sponsored Pharmaceutical Executive interview with Acumetis makes that case in general terms. The JCA rules supply the specifics: what is fixed, and when.

What the JCA fixes early

Regulation (EU) 2021/2282 entered into force on 11 January 2022 and applies from 12 January 2025. From that date, new cancer medicines and advanced therapy medicinal products fall under the JCA.

For a marketing authorisation application submitted to the EMA after that date, the developer must send the summary of product characteristics and the clinical overview to the HTA secretariat at the same time. The Commission says this establishes the JCA scope. The process then formally begins when an assessor and a co-assessor are appointed.

The scope of the assessment is therefore anchored to the regulatory filing. A company that treats the filing as a regulatory event and starts access planning afterwards is working on a scope that is already being set.

Where the gaps open

The Acumetis interview describes regulatory, medical, HEOR, access and commercial teams working at different speeds under different governance. In its account, the gaps surface only when access teams engage, after decisions on endpoints, comparators and evidence plans are locked in. The piece contains no figures, so treat it as one adviser's view, not data.

The numbers that do exist come from pharmaphorum's one-year review of the JCA:

  • Letters of intent arrive late. They are expected about six months before EMA submission, yet 57% of those filed in 2025 were submitted late.
  • Indirect comparisons are fragile. The article reports that G-BA rejected 71.5% of indirect comparisons on methodological grounds, and that oncology indirect comparisons across five countries had a 30% acceptance rate, with France at 0%.
  • The response window is short. One consultant quoted says the 100-day window is "less than that" in practice.

The volume is also rising. The article cites a projection of about 58 JCAs at most for 2026, made up of roughly 35 oncology medicines, 15 advanced therapies, 3 variations and 5 medical devices. Orphan medicines follow in 2028 and all new medicinal products in 2030, with a Commission review of the JCA in 2028.

Pricing stays national

The JCA does not change who sets the price. The same review notes that pricing and reimbursement negotiations remain national and that the JCA excludes economic evaluations. Developers therefore need cost-effectiveness models aligned with the JCA's PICO parameters, because national bodies will still ask for them. The interviewee quoted says it is not yet known how influential JCA reports will be. Germany and France may recommend a product that Sweden declines on price grounds.

What it means for market access teams

  • Set the comparator logic before the pivotal trial reads out. Because the PICO set can include several countries' requests, subgroup analyses once needed mainly for Germany may be needed more widely. Plan the analyses in the protocol or statistical analysis plan, not after the fact.
  • Treat letters of intent as a milestone with an owner. A late letter is a sign that access is joining the programme after the filing plan is set.
  • Stress-test indirect comparisons early. If the comparator in a country's PICO has no head-to-head data, the indirect comparison will be examined hard. Agree the method with HEOR before the dossier is written.
  • Keep the economic model on the same evidence base. The JCA covers clinical evidence only, so the cost-effectiveness and budget impact work has to reuse the same comparators and populations, or payers will see two different stories.
  • Revisit launch sequencing and price corridors together. A JCA report gives every payer the same clinical read-out. How each country prices against it is still a national decision.

The launch plan stays, but the point at which it has to be tested moves from the weeks before launch to the design of the evidence package. To discuss how that affects your evidence plan, get in touch.